Abstract: An object of the present invention is to provide a composition that can be used as a novel anti-inflammatory agent. An inflammation such as stomatitis, oral mucositis, gingivitis, or pneumonia can be ameliorated and/or prevented by using a composition comprising olanexidine or a pharmacologically acceptable salt thereof. The composition of the present invention preferably further comprises a poloxamer which is a block copolymer consisting of a chain of polyoxypropylene (POP) and two chains of polyoxyethylene (POE) flanking the POP.

Abstract: An object of the present invention is to provide a substance capable of effectively suppressing the decrease in cell viability and the cell aggregation that occur when mammalian cells are preserved in a liquid, and less likely to adversely affect, when administered in vivo to a mammal, the body of the mammal, and a mammalian cell preservation liquid containing such a substance, and the like. Use of a liquid containing acarbose or a salt thereof and/or stachyose or a salt thereof for preserving a mammalian cell can effectively suppress the decrease in cell viability and the cell aggregation that occur when mammalian cells are preserved in a liquid. Further, the mammalian cell preserved in the liquid can be directly administered in vivo to a mammal, without being transferred into a new transplantation liquid.

Abstract: An object of the present invention is to provide a method capable of inexpensively and conveniently preparing cells having pluripotency and a very low risk of tumorigenic transformation.

Abstract: By using ion exchange column chromatography or calcium carbonate to an aqueous solution containing a compound A represented by the following formula and citric acid, citric acid in the aqueous solution is removed and a crystalline compound A is obtained by being thereafter subjected to several steps. Further a high-purity noncrystalline compound A is obtained by using calcium carbonate, sulfuric acid, an organic solvent and the like to the aqueous solution containing the compound A and citric acid to remove citric acid and the crystalline compound A in the solution. The configuration of the crystalline compound A is an SS isomer in the RS notation system. The configuration of the noncrystalline compound A is an SR isomer.

Abstract: An object of the present invention is to provide a crystal of an amino acid salt of HMB which is easy to handle and has high solubility, and to provide a method for producing the same. According to the present invention, the crystal of an amino acid salt of HMB can be precipitated by dissolving an amorphous amino acid salt of HMB in a solvent containing alcohol and stirring or allowing the solvent to left stand. In addition, the crystal of an amino acid salt of HMB can be precipitated by concentrating an aqueous HMB solution of an amino acid salt which has a pH of 2.5 to 11.0.

Abstract: An object is to provide a port that is capable of securely preventing pulling-out of a sealing plug from a port body. Provided is a port including: a sealing plug through which a hollow needle can be pierced; a port body having a hollow structure with the sealing plug disposed therein; and a pulling-out preventing member to be attached to the port body. The port body includes: a part to be sealed that has a tubular shape with a first end and a second end opposite to the first end, and is configured so that the sealing plug is sealingly inserted into the part to be sealed; a connection part that has a tubular shape, is continuous with the first end of the part to be sealed, and has an outer periphery connected to the bag body to be filled with a medical liquid; and a part to be fitted that is formed in any one of an inner peripheral surface of the part to be sealed, an outer peripheral surface of the part to be sealed, and the second end of the part to be sealed.

Abstract: An object of the present invention is to provide a crystal of an amino acid salt of HMB which is easy to handle and has high solubility, and to provide a method for producing the same. According to the present invention, the crystal of an amino acid salt of HMB can be precipitated by dissolving an amorphous amino acid salt of HMB in a solvent containing alcohol and stirring or allowing the solvent to left stand. In addition, the crystal of an amino acid salt of HMB can be precipitated by concentrating an aqueous HMB solution of an amino acid salt which has a pH of 2.5 to 11.0.

Abstract: The purpose of the present invention is to provide an ointment preparation in which both separation over time and discoloration over time are suppressed. Both separation over time and discoloration over time are suppressed in: a topical composition containing (A) 30-60 weight % of zinc chloride, a specific (B) inorganic powder and a specific (C) additive, and (D) a solvent; and a topical composition containing (A) 30-60 weight % of zinc chloride, a specific (B) inorganic powder, and (D) a solvent.

Abstract: An antiseptic composition with a more extended applicable range by further enhancing the efficacy of olanexidine gluconate, which has been used as a highly safe dermal bactericidal disinfectant, and extending antibacterial spectrum. The antiseptic composition includes and has a more extended bactericidal spectrum than conventional disinfectants.

Abstract: The present invention provides an intestinal flora extraction vessel for extracting an intestinal flora from feces, the vessel including: a vessel main body with a first opening portion and a second opening portion formed therein, the vessel main body being configured so as to be deformable; an opening/closing mechanism configured to open/close the first opening portion of the vessel main body; a filter member accommodated in the vessel main body and partitioning the vessel main body into a first region located on the side of the first opening portion and a second region located on the side of the second opening portion, the filter member being configured to filter off the intestinal flora from the feces; and a communication member attached to the second opening portion, and configured to allow the second region to be in communication with the outside of the vessel main body.

Abstract: Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).

Abstract: The present invention provides a method of producing a sheet-like pancreatic islet, comprising culturing an isolated pancreatic islet in a culture vessel, wherein a polypeptide comprising an EC1 domain of E-cadherin and having a binding ability to said E-cadherin is fixed on or applied to a surface of a solid phase, while being adhered to the solid phase surface for a period sufficient for the pancreatic islet to take a sheet-like form.

Abstract: An object of the present invention is to provide a composition that can be used as a novel anti-inflammatory agent. An inflammation such as stomatitis, oral mucositis, gingivitis, or pneumonia can be ameliorated and/or prevented by using a composition comprising olanexidine or a pharmacologically acceptable salt thereof. The composition of the present invention preferably further comprises a poloxamer which is a block copolymer consisting of a chain of polyoxypropylene (POP) and two chains of polyoxyethylene (POE) flanking the POP.

Abstract: When mammal cells are administered by using a container whose surface in contact with the mammal cells is formed of a fluororesin material at least partially having a —CF3 terminal group or a container whose surface in contact with the mammal cells is formed of a fluororesin material having a total number of non-fluorinated group terminals and —CF2H group terminals in the fluororesin of 70 or less per 1×106 carbon atoms, or mammal cells are stored or cultured in such a container, the cell adhesion on the container inner surface and the cell survival rate reduction can effectively be suppressed. Therefore, by using these containers, a mammal cell-containing liquid having a high concentration and a high proportion of living cells can be administered, stored or prepared, which contributes to regenerative medicine using the mammal cell-containing liquid (suspension liquid).

Abstract: The problem of the present invention is to provide a method for preserving mammalian cells over a long period of time using a solution for cell transplantation, capable of effectively suppressing cell death when the mammalian cells have been preserved, and the solution for cell transplantation. The present invention is characterized in that mammalian cells are preserved in a physiological aqueous solution for cell transplantation, comprising 2.0 to 6.0% (w/v) of trehalose, a derivative thereof, or a salt of trehalose or the derivative (a trehalose) and 4.0 to 7.0% (w/v) of dextran, a derivative thereof, or a salt of dextran or the derivative (a dextran). The effects of a trehalose and a dextran contained in the physiological aqueous solution for cell transplantation can suppress a decrease in the cell survival rate when mammalian cells are preserved for a long period of time (at least 14 days).

Abstract: The present invention provides an infusion preparation that is inhibited from generation of unwanted insoluble matter after mixing of two liquids of the infusion preparation in long-term storage. More specifically, the present invention provides an infusion preparation comprising two chambers separated by a communicably openable partition, a first chamber containing a first-chamber infusion comprising a fat emulsion and further comprising at least one member selected from the group consisting of amino acids that have a buffer action, divalent organic acids, and trivalent organic acids, a second chamber containing a second-chamber infusion comprising an amino acid and at least calcium as an electrolyte, wherein a total concentration of the amino acids that have a buffer action, divalent organic acids, and trivalent organic acids in the first-chamber infusion is 0.15 to 0.5 g/L, and a mixture of the first- and second-chamber infusions has a pH of 6.

Abstract: It is to provide a disinfectant liquid which enables easy identification of the application sites in preoperative skin disinfection and the like, where the liquid is obtained by coloring an aqueous solution of olanexidine gluconate which is a colorless and transparent liquid. A disinfectant liquid comprises olanexidine gluconate, a coloring agent such as Sunset Yellow FCF, an alkyl dimethylamine oxide such as lauryl dimethylamine oxide, and optionally one or more surfactants other than alkyl dimethylamine oxide such as polyoxyethylene alkyl ether including lauromacrogol and polyoxyethylene polyoxypropylene alkyl ether including polyoxyethylene(20) polyoxypropylene(4) cetyl ether. The disinfectant liquid enables easy identification of the application sites in preoperative skin disinfection and the like.

Abstract: An object of the present invention is to provide stem cells having excellent proliferation ability and differentiation ability. The present invention relates to stem cells isolated from a neonatal pig, and a preparation method therefor.

Abstract: The purpose of the present invention is to provide an adhesion prevention material capable of exhibiting excellent adhesion preventive effect. This adhesion prevention material concurrently uses: (A) a peptide (A-1) having an amino acid sequence-(X-Pro-Y)n-[wherein X represents an arbitrary defined amino acid, Pro represents proline, Y represents hydroxyproline or proline, and n is an integer between 1 and 10] and/or a peptide (A-2) having an amino acid sequence-(Pro-Y)m-[wherein Pro represents proline, Y represents hydroxyproline or proline, and m is an integer between 1-10]; and (B) a gelatin gel. This adhesion prevention material exhibits a dramatically enhanced adhesion preventive effect as compared with the case where the abovementioned components are used individually, and in particular, has a markedly superior effect against adhesion of tendons.